Wall Street Zen Upgrades AC Immune (NASDAQ:ACIU) to Hold

AC Immune (NASDAQ:ACIU) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities analysts also recently weighed in on the stock. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of AC Immune in a research note on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of AC Immune in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

AC Immune Stock Down 1.0%

ACIU stock opened at $2.93 on Friday. AC Immune has a 52-week low of $1.43 and a 52-week high of $4.00. The firm has a market cap of $294.20 million, a P/E ratio of -3.49 and a beta of 1.64. The company’s 50-day simple moving average is $3.20 and its 200-day simple moving average is $2.98.

Institutional Trading of AC Immune

Large investors have recently made changes to their positions in the company. EFG International AG purchased a new stake in shares of AC Immune in the fourth quarter valued at about $41,000. Private Advisor Group LLC purchased a new position in shares of AC Immune in the 3rd quarter valued at $48,000. Goldman Sachs Group Inc. lifted its stake in shares of AC Immune by 46.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 18,555 shares of the company’s stock worth $58,000 after purchasing an additional 5,920 shares in the last quarter. Susquehanna International Group LLP acquired a new position in AC Immune during the 3rd quarter worth approximately $63,000. Finally, Sei Investments Co. purchased a new position in shares of AC Immune in the second quarter valued at $51,000. 51.36% of the stock is owned by institutional investors and hedge funds.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.